Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 543

1.

TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi K.

J Neuroinflammation. 2011 Aug 9;8:92. doi: 10.1186/1742-2094-8-92.

2.

Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease.

Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K.

J Neuroinflammation. 2008 May 29;5:23. doi: 10.1186/1742-2094-5-23.

3.

Microglial response to LPS increases in wild-type mice during aging but diminishes in an Alzheimer's mouse model: Implication of TLR4 signaling in disease progression.

Go M, Kou J, Lim JE, Yang J, Fukuchi KI.

Biochem Biophys Res Commun. 2016 Oct 14;479(2):331-337. doi: 10.1016/j.bbrc.2016.09.073. Epub 2016 Sep 15.

PMID:
27641666
4.

Role of toll-like receptor signalling in Abeta uptake and clearance.

Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K.

Brain. 2006 Nov;129(Pt 11):3006-19. Epub 2006 Sep 19.

5.

Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease.

Couturier J, Stancu IC, Schakman O, Pierrot N, Huaux F, Kienlen-Campard P, Dewachter I, Octave JN.

J Neuroinflammation. 2016 Jan 27;13:20. doi: 10.1186/s12974-016-0477-y.

6.
7.

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.

Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW.

J Neuroinflammation. 2014 Jun 19;11:111. doi: 10.1186/1742-2094-11-111.

8.

Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade.

Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P.

J Neurochem. 2012 Feb;120(3):461-72. doi: 10.1111/j.1471-4159.2011.07594.x. Epub 2011 Dec 16.

9.

Gx-50 reduces β-amyloid-induced TNF-α, IL-1β, NO, and PGE2 expression and inhibits NF-κB signaling in a mouse model of Alzheimer's disease.

Shi S, Liang D, Chen Y, Xie Y, Wang Y, Wang L, Wang Z, Qiao Z.

Eur J Immunol. 2016 Mar;46(3):665-76. doi: 10.1002/eji.201545855. Epub 2016 Jan 21.

10.

A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K.

Neurobiol Dis. 2008 Jul;31(1):46-57. doi: 10.1016/j.nbd.2008.03.005. Epub 2008 Apr 7.

PMID:
18504134
11.

Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease.

Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM.

Neurodegener Dis. 2012;9(4):187-98. doi: 10.1159/000330363. Epub 2012 May 8.

PMID:
22584394
12.

Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice.

Seabrook TJ, Jiang L, Maier M, Lemere CA.

Glia. 2006 May;53(7):776-82.

PMID:
16534778
13.

Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.

Cameron B, Tse W, Lamb R, Li X, Lamb BT, Landreth GE.

J Neurosci. 2012 Oct 24;32(43):15112-23. doi: 10.1523/JNEUROSCI.1729-12.2012.

14.

Attenuation of microglial activation in a mouse model of Alzheimer's disease via NFAT inhibition.

Rojanathammanee L, Floden AM, Manocha GD, Combs CK.

J Neuroinflammation. 2015 Mar 4;12:42. doi: 10.1186/s12974-015-0255-2.

15.

CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.

Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM, Lamb BT.

Am J Pathol. 2010 Nov;177(5):2549-62. doi: 10.2353/ajpath.2010.100265. Epub 2010 Sep 23.

16.

Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.

Kawahara K, Suenobu M, Ohtsuka H, Kuniyasu A, Sugimoto Y, Nakagomi M, Fukasawa H, Shudo K, Nakayama H.

J Alzheimers Dis. 2014;42(2):587-605. doi: 10.3233/JAD-132720.

PMID:
24916544
17.

Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice.

Babcock AA, Ilkjær L, Clausen BH, Villadsen B, Dissing-Olesen L, Bendixen AT, Lyck L, Lambertsen KL, Finsen B.

Brain Behav Immun. 2015 Aug;48:86-101. doi: 10.1016/j.bbi.2015.03.006. Epub 2015 Mar 12.

PMID:
25774009
18.

Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.

Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T.

Glia. 2010 Feb;58(3):300-14. doi: 10.1002/glia.20924.

19.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
20.

A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.

Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC.

J Alzheimers Dis. 2010;20(1):113-26. doi: 10.3233/JAD-2010-1349.

PMID:
20164597

Supplemental Content

Support Center